TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
BOSTON, Dec. 11, 2015 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced that it will host a conference call and webcast slide presentation on Wednesday, December 16, 2015 at 4:30 PM ET to provide a corporate update and discuss the Company's 2016 outlook.
The call can be accessed by dialing (877) 751-7350 (U.S. and Canada) or (918) 559-5237 (international). The passcode for the conference call is 6055343. To access the slide and live audio webcast, or the subsequent archived recording, visit the "Investors & Media" section of the ZIOPHARM website at www.ziopharm.com. The webcast will be recorded and available for replay on the Company's website for two (2) weeks.
About ZIOPHARM Oncology, Inc.:
ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression, control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer. The Company's synthetic immuno-oncology programs, in collaboration with Intrexon Corporation (NYSE:XON) and the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T) and other adoptive cell based approaches that use non-viral gene transfer methods for broad scalability. The Company is advancing programs in multiple stages of development together with Intrexon Corporation's RheoSwitch Therapeutic System® technology, a switch to turn on and off, and more precisely modulate gene expression in order to improve therapeutic index. The Company's pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies.
CONTACT: Lori Ann Occhiogrosso
ZIOPHARM Oncology, Inc.
617-259-1987
[email protected]
David Pitts
Argot Partners
212-600-1902
[email protected]
